Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin P Rock

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Pharmacy Practice|January 2, 2023
Adverse Drug Reaction vs Care Complication: Response to "Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematous"Carolyn E Ragsdale, Edwin P Rock
Frontiers in Immunology|February 24, 2023
Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysisIla Joshi, Walter P Carney, Edwin P Rock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
GCP data quality for early clinical developmentEdwin P Rock, Vernette J Molloy, Jeffrey S Humphrey
Journal of Neuro-Oncology|March 28, 2012
Refining endpoints in brain tumor clinical trialsChristina A Meyers, Edwin P Rock, Howard A Fine
Cureus|July 10, 2024
Selectins in Biology and Human Disease: Opportunity in E-selectin AntagonismJohn M Peterson, Theodore A Smith, Edwin P Rock, et al.
Journal of the National Cancer Institute. Monographs|October 24, 2007
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer productsEdwin P Rock, Jane A Scott, Dianne L Kennedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Patient-reported outcomes supporting anticancer product approvalsEdwin P Rock, Dianne L Kennedy, Melissa H Furness, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Role of Fcγ receptors in HER2-targeted breast cancer therapyAntonino Musolino, William J Gradishar, Hope S Rugo, et al.
The Oncologist|January 18, 2007
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinomaEdwin P Rock, Vicki Goodman, Janet X Jiang, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 13, 2007
Patient-reported outcomes to support medical product labeling claims: FDA perspectiveDonald L Patrick, Laurie B Burke, John H Powers, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Pharmacy Practice|January 2, 2023
Adverse Drug Reaction vs Care Complication: Response to "Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematous"Carolyn E Ragsdale, Edwin P Rock
Frontiers in Immunology|February 24, 2023
Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysisIla Joshi, Walter P Carney, Edwin P Rock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
GCP data quality for early clinical developmentEdwin P Rock, Vernette J Molloy, Jeffrey S Humphrey
Journal of Neuro-Oncology|March 28, 2012
Refining endpoints in brain tumor clinical trialsChristina A Meyers, Edwin P Rock, Howard A Fine
Cureus|July 10, 2024
Selectins in Biology and Human Disease: Opportunity in E-selectin AntagonismJohn M Peterson, Theodore A Smith, Edwin P Rock, et al.
Journal of the National Cancer Institute. Monographs|October 24, 2007
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer productsEdwin P Rock, Jane A Scott, Dianne L Kennedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Patient-reported outcomes supporting anticancer product approvalsEdwin P Rock, Dianne L Kennedy, Melissa H Furness, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Role of Fcγ receptors in HER2-targeted breast cancer therapyAntonino Musolino, William J Gradishar, Hope S Rugo, et al.
The Oncologist|January 18, 2007
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinomaEdwin P Rock, Vicki Goodman, Janet X Jiang, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 13, 2007
Patient-reported outcomes to support medical product labeling claims: FDA perspectiveDonald L Patrick, Laurie B Burke, John H Powers, et al.
Pageof 2